This stock is TD Cowen’s Top Pick After Strong Q2

TD Cowen reiterated Rhythm Pharmaceuticals (NASDAQ:RYTM) as a top pick with a $130 price target and Buy rating after strong Q2 results. Imcivree revenue rose to $71.3M (+19% QoQ, +47% YoY) and beat estimates of ~$67M, driven by U.S. revenue up 38% to $51M. The pipeline also showed positive proof-of-concept with RM-718 delivering an 11.6% BMI reduction at 16 weeks, supporting plans to advance an MC4R agonist into a 6-month Prader-Willi pivotal trial.

Analysis

RYTM is increasingly looking like a commercial-only story today and a platform story over the next 6-18 months. The key market mechanism is not the quarter itself; it is whether the company can convert a concentrated rare-disease prescriber base into a durable refill engine before the next pipeline readout. If the launch keeps compounding at a similar rate, the stock can de-rate the usual “single-asset biotech” discount and trade more like a specialty pharma with a second growth leg.

The second-order implication is competitive: stronger uptake in hypothalamic-obesity and Bardet-Biedl syndrome raises the bar for any adjacent rare-obesity entrant, because physician familiarity and reimbursement precedent become real moats. That said, this is still a small, fragile funnel—400 prescribers is enough for momentum, not enough for complacency. The biggest risk is that current growth is front-loaded from diagnosis catch-up and patient conversion; if new starts slow or persistence weakens, the market will quickly reprice the durability of the opportunity.

The contrarian view is that consensus may be underestimating the platform optionality in the MC4R class, but overestimating how quickly it becomes visible in financials. The next catalyst path is 1-3 months of prescription cadence and management commentary, then a 6-12 month binary on the Prader-Willi trial. Falsifiers are straightforward: sequential U.S. growth slowing materially, weaker reimbursed-patient expansion, or any sign the pivotal program is drifting in endpoint design or timing.

Key Decisions for Investors

• Long RYTM on pullbacks over the next 2-6 weeks; favor entry after any post-earnings digestion. Risk/reward works if the market keeps rewarding commercial acceleration ahead of the PWS catalyst.
• Pair trade: long RYTM / short XBI for the next 1-3 months. Thesis is company-specific execution and de-risking versus a crowded biotech index exposed to financing and trial volatility.
• If options liquidity is adequate, buy 3-6 month RYTM calls on a dip rather than chasing common after a strong print. The goal is convexity into the next prescription update without paying full implied move.
• Set an alert for next-quarter U.S. revenue growth and patient adds; if sequential growth drops sharply, trim. That would indicate the launch is moving from acceleration to saturation.
• Watch the PWS trial timeline as the structural catalyst. Any delay or softer endpoint framing should be treated as a thesis reset, not a buying opportunity.